8 results about "Rosiglitazona" patented technology

The invention discloses a method for efficiently detecting trace residues of'three-high 'drugs in fish plasma, the'three-high' drugs comprise triamterene, terazosin, rosiglitazone, lovastatin, benazepril, pitavastatin and repaglinide, and the method comprises the following steps: adding an anticoagulant into a collected fish plasma sample, centrifuging, taking supernate, and collecting the supernate; the method comprises the following steps: firstly, adding an internal standard solution, adding acetone containing formic acid with the volume fraction of 1% into a purification tube, loading a labeled sample, pressurizing to ensure that the sample drips in a drop shape, collecting by using a polypropylene test tube containing a purification reagent, oscillating and purifying, centrifuging, taking supernate, and concentrating to obtain a concentrated solution; the method disclosed by the invention is high in sensitivity, and the detection limit range of seven kinds of drugs for target'three highs' in the blood plasma of the aquatic environment fish is 0.02-0.25 ng / mL.

This application belongs to the field of biomedical technology. This application discloses an antitumor agent and its application. The antitumor agent of this application comprises: (a) rosiglitazone; (b) one or more inhibitors for reducing the expression of fructose-1,6-bisphosphate aldolase C. The antitumor agent of this application can more effectively inhibit the proliferation of tumor cells and can be used as a potential antitumor agent.

According to the application of the rosiglitazone in preparation of the medicine for treating the glioma and the composition of the rosiglitazone, a brand-new Rb-E2F1-mediated MND1 transcription inhibition mechanism of the rosiglitazone in the glioma is clarified for the first time; and a new strategy with a great transformation prospect is provided for treatment of glioma, namely, a clinical drug rosiglitazone which has been subjected to security certification is utilized to interfere DNA repair steady state of glioma cells through targeted inhibition of MND1, so that tumor growth is inhibited.

The application discloses application of forsythoside in preparation of a medicine for preventing edema caused by rosiglitazone, and belongs to the technical field of biological medicine. In view of the problem that rosiglitazone can cause edema side effect when treating type 2 diabetes, the application uses forsythoside and rosiglitazone in combination, rosiglitazone can relieve type 2 diabetes, and forsythoside can effectively reduce edema caused by rosiglitazone, so that the side effect of rosiglitazone medicine can be obviously reduced, and the dosage of rosiglitazone can be reduced. The application provides a new safe and effective medicine combination for treating and preventing insulin resistance diseases, and provides a theoretical guidance for preventing and treating the edema side effect of rosiglitazone.

The invention belongs to the technical field of rapid screening and toxicity evaluation of new pollutants, and discloses a PPAR gamma active substance screening method based on PPAR gamma / RXR alpha heterodimerization. The method is used for detecting the PPAR gamma agonistic / antagonistic activity of chemicals. Aiming at the problems of incomplete biological process simulation, low sensitivity and the like existing in the conventional common reporter gene screening method, the invention constructs a novel screening method: firstly, introducing a chaperone nuclear receptor RXR alpha, and constructing a screening method based on PPAR gamma / RXR alpha heterodimerization so as to more accurately simulate an in-vivo regulation mechanism; and secondly, a co-activation factor NCOA6 (PRIP) is innovatively introduced, the transfection quality is determined to be 50-200ng, and the signal response intensity of the reporter gene is effectively enhanced. Through the work, the lowest effect concentration (LOEC) of the PPAR gamma active substance screening method on the PPAR gamma positive substance rosiglitazone (ROSI) is reduced from 1 mu M to 10 nM, the EC50 value is reduced to 213.4 nM, and the sensitivities are improved by 2.7 times and 100 times respectively. The method is easy and convenient to operate and suitable for efficient and accurate detection of low-concentration PPAR gamma active substances in the environment.

The invention discloses a system for promoting in-vitro differentiation of chicken oogonial stem cells and forming blastocysts, and belongs to the technical field of stem cell differentiation culture. According to the invention, retinoic acid (RA) and vitamin C (VC) are added on the basis of an oogonial stem cell culture medium to induce cells to start meiosis, and then follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), glial cell-derived neurotrophic factor (GDNF), progesterone (P4) and rosiglitazone are further added on the basis of the culture medium containing RA and VC to promote the recovery of meiosis, so that the effect of promoting meiosis is achieved. A complete system that the chicken oogonial stem cells are differentiated in vitro and form blastocysts is creatively established by inducing formation of secondary oocytes, direct evidence is provided for in-vitro reconstruction of poultry ovum generation, and a technical basis and application prospects are provided for preservation of female germ cells and large-scale production of the chicken oocytes.

Methods for treating a disease, condition, or disorder associated with impaired muscle regeneration, including a muscular dystrophy, such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), or limb-girdle muscular dystrophy (LGMD), by administering a PPARγ agonist to a subject. The PPARγ agonist can be one or more thiazolidinediones including, but not limited to pioglitazone and rosiglitazone.

The invention belongs to the technical field of biological medicine. The invention discloses an anti-tumor preparation and application thereof. The anti-tumor preparation of the present application comprises: (a) rosiglitazone; and (b) one or more inhibitors for reducing the expression of fructose-1, 6-diphosphate aldolase C. The invention also relates to a method for producing the same. The anti-tumor preparation can more effectively inhibit proliferation of tumor cells, and can be used as a potential anti-tumor preparation.